Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood marker may reveal kidney trouble early in heart failure patients

NCT ID NCT00561483

Knowledge-focused Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study looked at 64 adults hospitalized for acute heart failure to see if a blood marker called cystatin C could detect early kidney problems caused by diuretic treatment. Researchers measured cystatin C levels daily and compared them to standard kidney tests. The goal was to understand how kidney function changes during treatment and whether cystatin C could help predict worsening kidney function in the future.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

64 people

The number who actually took part.

Started

Dec 2007

Finished

Oct 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients admitted to the hospital with decompensated heart failure

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hospital admission within 48 hours for ADHF, with an expected stay over 24 hours. * Evidence of fluid overload, including jugular venous distention, pulmonary rales, peripheral edema, and/or ascites receiving diuretic therapy Exclusion Criteria: * Heart failure due to congenital heart disease or critical aortic stenosis (potentially different cardio-renal pathophysiology) * Acute myocardial infarction or unstable acute coronary syndromes * End-stage renal insufficiency on renal replacement therapy (already has underlying advanced renal failure). * Patients with active cancer (cystatin C has been shown to be produced by some tumors) * Known exposure to nephrotoxic agents (such as contrast dye) or planned surgery during hospitalization at the time of enrollment * Hemoglobin \< 9 mg/dL or clinically significant active bleeding. * Unable to comply with protocol or unable to have informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute heart failure Renal failure

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.